



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	10/037,480-Conf. #5210
Filing Date	January 4, 2002
First Named Inventor	Gregor Cevc, et al.
Art Unit	1723
Examiner Name	A. M. Fortuna
Attorney Docket Number	56822 (47126)

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
AF	AA	US-6,835,392-B2	12-28-2004	Hsu, et al.	
	AB	US-6,562,370-B2	05-13-2003	Luo, et al.	
	AC	US-6,582,724-B2	06-24-2003	Hsu, et al.	
	AD	US-6,586,000-B2	07-01-2003	Luo, et al.	
	AE	US-6,645,520-B2	11-11-2003	Hsu, et al.	
AF	AF	US-2002/0048596	04-25-2002	Cevc	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
AF	BA	CA-2 067 754	03-05-1992	IDEA AG		
AF	BB	EP-0 995 435	04-26-2000	SENJU PHARMACEUTICAL CO., LTD.		
AF	BC	EP-0 382 716	01-28-1998	WARNER-LAMBERT CO.		
AF	BD	EP-0 355 095	08-04-1993	THE LIPOSOME COMPANY, INC.		
AF	BE	HU-0105400	05-29-2002	IDEA AG	English abstract corresponds to WO0044350	
AF	BF	HU-0104424	03-28-2002	IDEA AG	English abstract corresponds to WO0044350	
AF	BG	HU-9903363	03-28-2000	CEVC	English abstract corresponds to US2002/0048596	
AF	BH	WO-02/11683	02-14-2002	DOW PHARMACEUTICAL SCIENCES		
AF	BI	WO-02/07767	01-31-2002	ALCON UNIVERSAL LTD.		
AF	BJ	WO-01/12155	02-22-2001	LIPOCINE, INC.		
	BK	WO-00/50007	08-31-2000	LIPOCINE, INC.		
	BL	WO-00/44350	08-03-2000	IDEA AG		
	BM	WO-00/38653	07-06-2000	IDEA INNOVATIVE DERMALE APPLICATIONEN GMBH		
	BN	WO-00/25822	05-11-2000	John C. Grasela, et al		
	BO	WO-00/13684	03-16-2000	LOMA LINDA UNIVERSITY MEDICAL CENTER		
AF	BP	WO-98/07414	02-26-1998	RESEARCH TRIANGLE PHARMACEUTICALS LTD.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind's Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	12/29/05
-----------------------	--	--------------------	----------



PTO/SB08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1996, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/037,480-Conf. #5210
				Filing Date	January 4, 2002
				First Named Inventor	Gregor Cevc, et al.
				Art Unit	1723
				Examiner Name	A. M. Fortuna
Sheet	2	of	2	Attorney Docket Number	56822 (47126)

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
AK	CA	Prof. Dr. K-U Benner, "Der Korper des Menschen", page 49 (1995).	
	CB	SERVA Feinbiochemica, Katalog, pages 201-202 (1986/1987).	
	CC	FLUKA Chemica-BioChemica, Katalog 16, pages 204, 830 (1988/1989).	
	CD	Louis F. Fieser, Mary Fieser, "Organische Chemie", page 1250 (1968).	
	CE	J. Roeding, "Visualisierungstechniken von vesikularen Systemen, Wechselwirkungen von Liposomen mit der Haut", Kurs 502 of APV, (May 14-16, 1990).	
	CF	Hans Schreier, "Liposomen - ein neuartiger Arzneistofftrager", Pharmazie in unserer Zeit, pages 97-108 (1982).	
	CG	D. Lichtenberg, "Solubilization of Phospholipids by Detergents Structural and Kinetic Aspects", Biochimica et Biophysica Acta, pages 285 - 304 (1983).	
	CH	Reviews on Biomembranes, Biochimica et Biophysica Acta, Vol. 415 No. 1, pages 29-79 (1975).	
	CI	M. L. Jackson, et al., Solubilization of Phosphatidylcholine Bilayers by Octyl Glucoside, Biochemistry, Vol. 21, pages 4576-4582 (1982).	
	CJ	P. K. Vinson, et al., "Vesicle-micelle transition of phosphatidylcholine and octyl glucoside elucidated by cryo-transmission electron microscopy", Biophysical Journal, Vol 56, pages 669-681 (1989).	
	CK	K. Edwards, et al., Effects of Triton X-100 on Sonicated Lecithin Vesicles, Langmuir, Vol. 5, pages 473-478 (1989).	
	CL	A. Brendzel, et al., Effects of Lipid-Soluble substances on the Thermotropic Properties of Liposome Filtration", Biochimica et Biophysica Acta, Vol. 601, pages 260 - 270 (1980).	
	CM	C. Beyer, "Mikroemulsionen", Pharmazie in unserer Zeit, pages 55-60 (1983).	
	CN	J. Lasch, et al., " Interactions of external lipids (lipid vesicles) with the skin", Journal of Liposome Research, Vol. 5, No. 3, pages 543-569 (1995).	
	CO	M. Berger, "Oral Insulin 1922-1992: The History of Continuous Ambition and Failure", Heinrich-Heine-University, Düsseldorf, Germany.	
CP	G. Cevc, et al., "The skin: a pathway for systemic treatment with patches and lipid-base agent carriers", Adv. Drug Delivery Reviews, Vol. 18, pages 349-378 (1996).		

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ³Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	12/09/05
--------------------	--	-----------------	----------

494023